“Certain cancer treatments can increase a patient’s risk of heart disease, atherosclerosis and diabetes, just to name a few. By using this algorithm, we may be reducing these risks and ultimately avoiding adverse outcomes in these at-risk patients,” said study co-author David Penson, MD, MPH, who is a professor of urologic oncology at Vanderbilt University.
Clinicians must balance the appropriate use of lipid-lowering therapy, antihypertensive therapy, and glucose-lowering therapy in these patients. It is hoped that this approach will help better stratify the risks and benefits of ADT in individual patients.
“Many of the treatments we use to cure and control cancer increase the chances of patients developing CVD. Using the algorithm ensures that we are addressing two major potential causes of mortality as opposed to just one,” Dr Penson told Cancer Therapy Advisor.
Robert Bonow, MD, who is the American Heart Association past-president and a professor of cardiology at Northwestern University, Chicago, IL, said this algorithm may help prevent many CVD events. He expects that many more men than in the past will have to weigh the risks and benefits of ADT in combating prostate cancer.
- Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537-541.
- Levine GN, D’Amico AV, Berger P; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, American Cancer Society, and American Urological Association. Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833-840.